Fundraising Fox
Eidos Therapeutics
Unicorn exit · $1BAcquiredSan Francisco, US · Founded 2013 · 5 known investors
Find your way into Eidos Therapeutics
Sign up to see every warm intro you have to Eidos Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eidos Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by BridgeBio Pharma January 2021 · $1B ($1.03 billion for remaining 36.35% stake (also cited as $2.83B overall transaction value)) · source ↗
A digital health resource platform providing medical professionals with educational information and clinical resources about transthyretin amyloid cardiomyopathy (ATTR-CM) and related cardiac and neurological conditions.
Founders & leadership
Eidos Therapeutics was founded in 2013 by NEIL KUMAR.
Board
Investors · 5
How we know: Aisling Capital's portfolio page · a partner's Signal profile · board seat on SEC Form D · press coverage · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · press coverage · Not right? Tell us
How we know: Viking Global's portfolio page · Not right? Tell us
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$26M disclosed across 1 round · 2018
▶$26MraisedApr 2018 · 13 investors · BiotechnologyRule 506(b)
- RAJEEV SHAHDirector
- JONATHAN FOXExecutive Officer
- UMA SINHAExecutive Officer
- HOYOUNG HUHDirector
- NEIL KUMARExecutive Officer, Director
- ERIC AGUIARDirector
- CHRISTINE SIUExecutive Officer
- Offering amount
- $74M
- Amount sold
- $26M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Eidos Therapeutics do?
- A digital health resource platform providing medical professionals with educational information and clinical resources about transthyretin amyloid cardiomyopathy (ATTR-CM) and related cardiac and neurological conditions.
- Who founded Eidos Therapeutics?
- Eidos Therapeutics was founded by NEIL KUMAR in 2013.
- Who are Eidos Therapeutics's investors?
- Eidos Therapeutics's investors include Aisling Capital, Foresite Capital, RA Capital, Viking Global, Viking Global Investors.
- How much funding has Eidos Therapeutics raised?
- Eidos Therapeutics has disclosed $26M raised across 1 round.
- Where is Eidos Therapeutics headquartered?
- Eidos Therapeutics is headquartered in San Francisco, US.